Loading
Life sciences · Journal article
BMC Cancer · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Malignant peripheral nerve sheath tumours (MPNSTs) are high grade soft-tissue sarcomas with an unmet need for novel therapies. Tumour antigen-based approaches, including neoantigen and tumour-associated antigens (TAA) directed therapies, offer potential opportunities for immunotherapy. Here, we integrated public domain tumour DNA and RNA sequencing data with in-silico predictions in order to characterise the potential (neo)antigenic landscape of MPNST. We stratified the computational predictions across the two known sub-groups of MPNST, those associated without and with Polycomb Repressor Complex 2 (PRC2) loss of function variants (PRC2-Loss). Using pVACtools, computationally identified high-confidence neoantigens based on predicted pMHC affinity were derived from somatic mutations and gene fusions, as well as recurrently overexpressed cell-surface TAAs. All predicted neoantigens were private to individual MPNST cases and across both tumour subtypes. Using ImSig and CIBERSORTx, PRC2-Loss tumours displayed reduced immune infiltration with downregulation of antigen processing and presentation pathways compared to PRC2-WT, confirming known intrinsic constraints to effective neoantigen-directed immune priming. Moreover, PRC2-Loss MPNSTs demonstrated recurrent copy number driven overexpression of cell surface TAAs derived from chromosome 8 amplification, providing potential immunotherapeutic targets that are pMHC independent. Overall, these predictive findings confirm a PRC2-independent private immuno-antigenic peptide repertoire, with an immune resistant MPNST microenvironment in PRC-Loss. These data provide further impetus for personalised functional validation and immune based treatment strategies, including personalised neoantigen vaccines and cell surface protein TAA-directed therapies dependent on PRC2 status.